# Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

Study · id `cardio:ct-nct02675790` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02675790](<https://clinicaltrials.gov/study/NCT02675790>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02675790

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 120 participants.

## Technical summary

Registry record NCT02675790. Randomized; quadruple masking; primary purpose prevention. Start 2017-01 (actual); primary completion 2020-03-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT02675790, source copy `cardio:ctgov-nct02675790-2022-01-19`, retrieved 2026-10-26)
- Started: 2017-01 (actual) (ClinicalTrials.gov record NCT02675790, source copy `cardio:ctgov-nct02675790-2022-01-19`, retrieved 2026-10-26)
- Primary completion: 2020-03-31 (actual) (ClinicalTrials.gov record NCT02675790, source copy `cardio:ctgov-nct02675790-2022-01-19`, retrieved 2026-10-26)
- Completion: 2020-03-31 (actual) (ClinicalTrials.gov record NCT02675790, source copy `cardio:ctgov-nct02675790-2022-01-19`, retrieved 2026-10-26)
- Countries: Nigeria (ClinicalTrials.gov record NCT02675790, source copy `cardio:ctgov-nct02675790-2022-01-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02675790-2022-01-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
- Acronym: SPRINT
- Condition: Sickle Cell Disease
- Condition: Sickle Cell Anemia
- Condition: Stroke
- Intervention (Drug): Moderate Dose Hydroxyurea
- Intervention (Drug): Low Dose Hydroxyurea
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: Aminu Kano Teaching Hospital
- Collaborator class: OTHER
- Collaborator: Murtala Muhammed Specialist Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: Aminu Kano Teaching Hospital (`cardio:org-aminu-kano-teaching-hospital`)
- Registry lists this organization as a collaborator: Murtala Muhammed Specialist Hospital (`cardio:org-murtala-muhammed-specialist-hospital`)

## Provenance

Content hash: a6a2f50bb4baa9f434c14e1bccb94641c935f71a1fd15c1e7c8d1b724fca7722
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
